epidiolex

  1. Ron Strider

    Here's What Caused This Marijuana Stock To Skyrocket 15% In November

    Medical marijuana has been used to treat epilepsy in patients for years, but so far, it's efficacy and safety hasn't been supported by a regulatory green light from the Food and Drug Administration (FDA). Based on recently reported results for Epidiolex, a cannabidiol epilepsy medicine, that...
  2. Ron Strider

    CBD Medication Breakthrough: Is Pharmaceutical Firm's Boon The Hemp Industry's Doom

    This time next year, an investigational drug hailed as a breakthrough in the science of cannabidiol could be prescribed to children suffering from treatment-resistant epilepsy. The prospect of its success, however, has caused some unease in the American hemp industry. London-based GW...
  3. Ron Strider

    Will These Be The Top Marijuana Stocks To Own In 2018

    The marijuana market is growing rapidly and that's creating a lot of interest in owning marijuana stocks. However, investors need to pick what marijuana stocks to buy carefully. There's likely to be more losers in this industry than winners, and it could be a long time before any of these...
  4. Ron Strider

    How Big Is The Marijuana Stock Opportunity In Cannabidiol

    A lot of progress is being made on understanding how marijuana's chemical cannabinoids can be used as medicine, and among the most intriguing of these cannabinoids is cannabidiol, or CBD. It's one of at least 113 active cannabinoids found in marijuana, it's not responsible for marijuana's...
  5. Ron Strider

    Marijuana Legalization Could Hurt These Marijuana Stocks

    Support of marijuana legalization is at an all-time high. States across the country have legalized marijuana, either for medical use, recreational use, or both. You might think that every marijuana stock would benefit from these trends. But that's not the case. One company with a cannabinoid...
  6. K

    GW Pharmaceutical Gets Closer To Forcing FDA On Cannabis

    British biotech company GW Pharmaceuticals announced positive results on its latest Phase 3 clinical trial for its drug Epidiolex. The drug is cannabidiol-based and is used to treat children with Lennox-Gastaut syndrome, a rare form of childhood epilepsy. The results from the test were very...
  7. K

    GW Pharmaceutical Gets Closer To Forcing FDA On Cannabis

    British biotech company GW Pharmaceuticals announced positive results on its latest Phase 3 clinical trial for its drug Epidiolex. The drug is cannabidiol-based and is used to treat children with Lennox-Gastaut syndrome, a rare form of childhood epilepsy. The results from the test were very...
  8. K

    Third Win For Cannabis Drug In Epilepsy Sends GW To Record High

    An experimental cannabis-derived drug has successfully treated children with severe epilepsy in a third late-stage clinical trial, sending shares in Britain's GW Pharmaceuticals to a record high on Monday. GW, which was founded in 1998 to capitalize on the medical benefits of cannabis, said...
  9. K

    Third Win For Cannabis Drug In Epilepsy Sends GW To Record High

    An experimental cannabis-derived drug has successfully treated children with severe epilepsy in a third late-stage clinical trial, sending shares in Britain's GW Pharmaceuticals to a record high on Monday. GW, which was founded in 1998 to capitalize on the medical benefits of cannabis, said...
  10. K

    Here's Why This Marijuana Stock Marched 10.6% Higher In June

    What: After reporting that its marijuana-derived drug Epidiolex reduced the number of monthly seizures in patients with Lennox-Gastaut syndrome, GW Pharmaceuticals Plc shares jumped 10.6% last month, according to S&P Global Market Intelligence. So what: Earlier this year, a phase 3 trial in...
  11. K

    Here's Why This Marijuana Stock Marched 10.6% Higher In June

    What: After reporting that its marijuana-derived drug Epidiolex reduced the number of monthly seizures in patients with Lennox-Gastaut syndrome, GW Pharmaceuticals Plc shares jumped 10.6% last month, according to S&P Global Market Intelligence. So what: Earlier this year, a phase 3 trial in...
  12. K

    Marijuana-Based Drug Helps Kids With Rare Forms Of Epilepsy In Studies

    An oil derived from marijuana plants proved effective in a rare form of epilepsy that afflicts 30,000 Americans, its maker said this morning. GW Pharmaceuticals, a London-based company, is developing a drug called Epidiolex, a pharmaceutical-grade form of cannabidiol (CBD), an oil found in...
  13. K

    Marijuana-Based Drug Helps Kids With Rare Forms Of Epilepsy In Studies

    An oil derived from marijuana plants proved effective in a rare form of epilepsy that afflicts 30,000 Americans, its maker said this morning. GW Pharmaceuticals, a London-based company, is developing a drug called Epidiolex, a pharmaceutical-grade form of cannabidiol (CBD), an oil found in...
  14. R

    GW Pharmaceuticals Seeks FDA Approval For Cannabis Based Epidiolex

    Children afflicted with Dravet Syndrome, a rare form of epilepsy, have been effectively treated with a cannabis-based drug, Epidiolex, containing cannabinoids, the GW Pharmaceuticals announced Monday. Investors snapped up shares of the little-known firm, effectively doubling the company's market...
  15. R

    Cannabis Drug Succeeds In Epilepsy, Doubling Value Of GW Pharma

    An experimental cannabis-based drug has successfully treated children with a rare form of severe epilepsy in a keenly anticipated clinical trial, more than doubling the value of its maker GW Pharmaceuticals. The study of GW's Epidiolex in Dravet syndrome is the first of four final-stage Phase...